BSECompany Update6d ago · 3 Nov 2026, 04:27 pm
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Patanjali Foods Ltd · 500368
✦ AI SummaryRegulatory
Patanjali Foods Ltd has received a communication from the Food and Drug Administration (FDA), Maharashtra, regarding a stock of Patanjali Cow Ghee held by one of its super distributors. The Company has not received any authenticated laboratory test report establishing that the samples have failed the prescribed quality parameters. The Company is taking cognizance of the matter and is seeking relevant details and supporting documents from the concerned FBO and the regulatory authorities.
Analysis Scores
Earnings Impact2/10
Growth Catalyst1/10
Governance Concern3/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment4/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Patanjali Foods Ltd - 500368 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Attachments (1)
📄pdf
Download →
3ce3a983-6941-4fe2-b554-867400aaa862.pdf
View document text
PFL/2026 November 03, 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Tower Exchange Plaza,
Dalal Street, Bandra Kurla Complex,
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
BSE Scrip Code: 500368 NSE Symbol: PATANJALI
Dear Sirs/Madam,
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we
wish to inform you that the Company has come to know about action initiated by the Food
and Drug Administration (FDA), Maharashtra, concerning certain stock of Patanjali Cow
Ghee held by one of its super distributor/Food Business Operators (FBO) in Maharashtra.
In this regard, we wish to place the following facts on record:
1. FDA communication not addressed to the Company
The communication/order in relation to the identified stock of Patanjali Cow Ghee was
issued to and received by the concerned super distributor/FBO. The said communication
has not been addressed or issued directly to the Company. The Company has been
informed of the matter by the concerned FBO and has obtained a copy of the
communication for its examination.
2. Sampling of Products and Status of Laboratory Reports
As per the information and documents made available to the Company, FDA officials
collected samples of the concerned batches of Patanjali Cow Ghee for laboratory
testing.
However, as on the date of this disclosure, neither the Company nor the concerned FBO
has received any authenticated laboratory test report establishing that the samples have
failed the prescribed quality parameters.
It is important to clarify that the collection of samples for testing, by itself, does not
establish adulteration, substandard quality or any violation of applicable food safety
standards.
3. Direction regarding the Identified Stock
As per the communication received by the concerned FBO, directions have been issued
regarding the identified stock, including restriction on its sale pending further action.
As per the communication available with the Company, the sampling of the product and
directions concerning the stock does not, by itself, contain any confirmed laboratory
finding establishing adulteration or failure of prescribed quality standards.
4. Company's commitment to quality and regulatory compliance
The Company reiterates its commitment to maintaining the highest standards of product
quality, consumer safety and regulatory compliance.
The Company is taking cognizance of the matter and is seeking relevant details and
supporting documents from the concerned FBO and the regulatory authorities. The
Company is fully willing to cooperate with the authorities and facilitate independent
verification of the concerned batches, as may be required.
In the event that any authenticated laboratory report establishes a deviation from the
prescribed quality standards, the Company shall examine the findings and take
appropriate corrective action in accordance with applicable laws and regulations.
5. Company's position and further developments
The Company believes that any conclusion regarding the quality or conformity of the
product should be based on authenticated laboratory findings and established
regulatory procedures.
At present, in the absence of any laboratory report establishing failure of the prescribed
quality parameters, it would be premature to conclude that the concerned product is
adulterated or substandard.
The Company is closely monitoring the matter and shall make further disclosures to the
Stock Exchanges, as may be required under applicable SEBI regulations, upon receipt of
any material developments or further directions from the concerned regulatory
authorities.
The Company remains committed to transparency, consumer confidence and
compliance with all applicable statutory and regulatory requirements.
This is for your information and records please.
Thanking you,
Yours Faithfully,
For Patanjali Foods Limited
Ramji Lal Gupta
Company Secretary